Stay updated with breaking news from Procisedx Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- ProciseDx Inc. announces that it has purchased two US patents in therapeutic drug monitoring (TDM) of biologic drugs to supplement its existing...
/PRNewswire/ -- ProciseDx Inc. announces that it is being acquired by Biosynex S.A., a French diagnostics company that specializes in point of care testing....
/PRNewswire/ -- ProciseDx Inc. announces FDA clearance of its ProciseDx instrument and C reactive Protein (CRP) test. Procise CRP gives quantitative...
ProciseDx Achieves CE Mark for Fecal Calprotectin Point of Care Testing News provided by Share this article Share this article SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- ProciseDx Inc. announced today that it has received CE mark for its Fecal Calprotectin (Procise FCP™) point of care tests for use on the ProciseDx™ system. Offering a point of care test for fecal calprotectin will help many physicians expedite their diagnosis of Crohn's Disease or Ulcerative Colitis, as well as other digestive conditions. The test can be completed in under 5 minutes with the ProciseDx platform. The Procis...